Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LX1001

Gene therapy (AAV vector) · Gene replacement · developed by Lexeo Therapeutics

Phase 1/2 Most advanced trial (none active)
LXEO Developer
1 Registered trials

What is LX1001?

LX1001 is a serotype rh.10 adeno-associated virus (AAV) gene transfer vector that carries the cDNA for human APOE2. It is studied in Alzheimer disease, including early onset Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AAVrh.10hAPOE2
Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Neurology
Developer
Lexeo Therapeutics (LXEO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03634007 Phase 1/2 Alzheimer Disease Completed LXEO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseEarly Onset Alzheimer Disease

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LXEO page.

Follow LXEO, the company behind LX1001

See LXEO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LXEO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.